Boston Scientific received CE mark approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES...
The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents, percutaneous transluminal coronary angioplasty (PTCA) and...
January 16, 2013 — Just weeks after the Food and Drug Administration (FDA) approved Cook Medical’s Zilver PTX drug-eluting peripheral stent, Riverside Methodist Hospital in Columbus,...
Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The randomized controlled trial will enroll about 2,250 patients and compare the performance of...
Abbott announced that the Xience Xpedition everolimus-eluting coronary stent system received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the...
Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top...
The U.S. Food and Drug Administration (FDA) granted market clearance for Cook Medical’s Zilver PTX drug-eluting peripheral stent. It is the first device of its kind on several fronts to go...
As the average age of the U.S. population and the number of patients at high risk for cardiovascular disease increase, the usage of cardio and endovascular stents continues to grow. Interventional...
Evaluating the performance of your cath lab is key to developing a strategic plan for improving service offerings, planning growth and expanding market share to compete for revenues. Availability...
